Floatz logo

Cixutumumab

Rhabdomyosarcoma

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

59 Active assets in the Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
Children's National Research Institute
Phase 2BB
Oxaliplatin
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
Calcium Phosphate
Children's Oncology Group
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3B

View all 50 →

Same molecule, other indications

Cixutumumab is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative · Phase 2
71 / 100
View asset →
Ewing sarcoma/peripheral primitive neuroectodermal tumorDormant
BB
Indicative · Phase 2
69 / 100
View asset →
prostate carcinomaDormant
BB
Indicative · Phase 2
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →